Transforming the Treatment of Chronic Pain
Moving Beyond Opioids
Transforming the Treatment of Chronic Pain
Moving Beyond Opioids
A VA Clinician’s Guide

VA PBM Academic Detailing Service
Real Provider Resources
Real Patient Results
Your Partner in Enhancing Veteran Health Outcomes

VA PBM Academic Detailing Service Email Group
PharmacyAcademicDetailingProgram@va.gov

VA PBM Academic Detailing Service SharePoint Site
https://vaww.portal2.va.gov/sites/ad

VA PBM Academic Detailing Public Website
http://www.pbm.va.gov/PBM/academicdetailingservicehome.asp
Transforming the Treatment of Chronic Pain

Major changes have occurred in the treatment of pain with the focus now on a biopsychosocial model of pain care using multimodal treatments. In 2011, drug overdoses became the leading cause of injury-related death in the United States rising above motor vehicle accidents. Due to the risks of using opioids, new guidelines recommend using non-pharmacologic and non-opioid treatments for chronic pain and recommend against using opioids.

Figure 1. Opioid Overdose Deaths Continue to Increase in the United States 2014–2015

Among 47,055 drug overdose deaths that occurred in 2014 in the United States, 28,647 (60.9%) involved an opioid. Centers for Disease Control (CDC) examined overall drug overdose death rates during 2010–2015 and opioid overdose death rates during 2014–2015 by subcategories (natural/semisynthetic opioids, methadone, heroin, and synthetic opioids other than methadone). Overdose death rates are continuing to increase with data from 2015, showing drug overdoses accounted for 52,404 U.S. deaths, including 33,091 (63.1%) that involved an opioid.

What Does This Really Mean?

91 Americans die every day from an opioid overdose (includes prescription opioids and heroin).
It is not just prescription opioids; heroin use is on the rise. Three out of four new heroin users report abusing prescription opioids before using heroin.²

Why are more people using heroin?
- Low cost
- Easily available
- Increased purity
- Increased potency

Fentanyl and other high potency synthetic opioids are being mixed with heroin creating a mixture that can be deadly. Fentanyl has also been detected in counterfeit opioid pills sold on the streets.

Veteran Specific Considerations

We, as a healthcare system, need to be vigilant about providing safe and effective pain care to Veterans with pain and identify those who may be seeking relief from psychological pain.³

Psychological distress may lead to inappropriate use of opioid medications.

Figure 2: Opioid Prescribing is More Common in Veterans with a Mental Health Diagnosis⁴

Iraq and Afghanistan Veterans who received a new non-cancer-pain diagnosis within 1 year of VA entry were followed for 1 year to evaluate whether an opioid was prescribed for ≥20 consecutive days. Veterans with post-traumatic stress disorder (PTSD) were more likely to be prescribed an opioid at higher doses, take opioids for longer than 2 months, and receive opioids and sedatives concurrently than patients without a mental health diagnosis. *Opioid use >33 mg MEDD.
**What Has the Department of Veterans Affairs (DVA) Done in Response?**

In 2013, the VA launched the Opioid Safety Initiative (OSI) to reduce the use of opioid medications, improve the safety of opioid prescribing, and expand alternative pain therapies. By 2016, measurable improvements were observed in metrics involving potentially unsafe opioid use.

**Figure 3. Opioid Prescribing Changes Since Implementing OSI in DVA**

- Number of Veterans dispensed an opioid
- Number of Veterans receiving daily opioid dosages of more than 100 mg morphine equivalent daily dose (MEDD)
- Number of Veterans receiving concomitant opioids and benzodiazepines

**What more can be done?**
Prevent the progression from acute to chronic opioid use.

It only takes 3 days of opioid treatment to see an increase in the risk of acute therapy extending into long-term therapy.

*Comparing data in mid-2016 to data from mid-2012.

**Figure 4: Any Use of Opioids for Acute Pain Increases the Probability of Chronic Opioid Use**

Records reviewed of patients ≥18 years of age who had at least one opioid prescription during June 1, 2006–September 1, 2015 and ≥6 months of continuous enrollment without an opioid prescription before their first opioid prescription. A total of 1,294,247 patients met inclusion criteria, including 33,548 (2.6%) who continued opioid therapy for more than 1 year.
**Change the Conversation**

We need to change our conversation to let Veterans know that we still want to address their pain using a whole-health approach to improve quality of life and increase functional status. Over time, this can lead to pain becoming less overwhelming.

**Table 1. Starting the Conversation with Veterans About Opioid Safety**

<table>
<thead>
<tr>
<th>When the conversation starts like this:</th>
<th>Instead of saying this:</th>
<th>Try saying this:</th>
</tr>
</thead>
<tbody>
<tr>
<td>Patient requests oxycodone for chronic low back pain</td>
<td>The VA says I cannot prescribe oxycodone any longer.</td>
<td>We have new information showing that opioids like oxycodone are not the best treatment for back pain. May I talk to you about treatments we have that may work better for you?</td>
</tr>
<tr>
<td>Patient on hydrocodone/acetaminophen for 3 years:</td>
<td>I know you have pain, but I cannot give you more hydrocodone and really we should not be using it at all. I am going to reduce your monthly supply in half this month.</td>
<td>May I talk to you about other treatments that might work better for your pain and are safer in the long run?</td>
</tr>
<tr>
<td>Patient who has been prescribed morphine Sustained Release (SR) for 8 years:</td>
<td>That morphine was prescribed by the VA provider you had before me.</td>
<td>Yes, this is a concern to me also.</td>
</tr>
<tr>
<td>Patient asks at his appointment why he has been prescribed such a dangerous drug after he hears on the news about the high rates of overdose</td>
<td>I never thought it was good for you.</td>
<td>We are realizing that opioids are not the best option for treating pain.</td>
</tr>
<tr>
<td></td>
<td>I am not sure how to taper you off of this, so I will send you to the pain clinic.</td>
<td>Just as treatments change for diseases like diabetes and heart disease, treatments can change for pain also.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Let’s talk about other options for your pain management. How does this sound to you?</td>
</tr>
</tbody>
</table>
Management of Chronic Pain

Management of chronic pain should be approached in a stepwise manner, with self-management and non-pharmacologic therapy used first line and tried before starting pharmacologic therapy. In some cases, for patients to start self-management activities, they may need to use a higher treatment step for a period of time. The goal of therapy is to maintain patients on the lowest treatment step.

Figure 5. Stepwise Approach to Chronic Pain Management

- **Step 1**: Self-management and optimized treatment of comorbidities
- **Step 2**: Self-management and treating comorbidities + Non-pharmacologic therapy
- **Step 3**: Self-management and treating comorbidities + Non-pharmacologic therapy + Non-opioid pharmacotherapy
- **Step 4**: Self-management and treating comorbidities + Non-pharmacologic therapy + Non-opioid pharmacotherapy + Intensive Interdisciplinary Pain Rehabilitation +/- Intermittent use of opioids for limited conditions (see p. 15)
**Self-management Education**

Self-management education and optimizing treatment of related comorbidities are recommended for all patients with chronic pain.

**Figure 6. Self-management Activities and Pain Management Strategies**

<table>
<thead>
<tr>
<th>General Health Promoting Activities</th>
</tr>
</thead>
<tbody>
<tr>
<td>• Practice mindfulness</td>
</tr>
<tr>
<td>• Healthy relationships</td>
</tr>
<tr>
<td>• Sleep hygiene</td>
</tr>
<tr>
<td>• Healthy eating</td>
</tr>
<tr>
<td>• Physical fitness/movement</td>
</tr>
<tr>
<td>• Tobacco cessation</td>
</tr>
<tr>
<td>• Engagement in activities that reflect personal values</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Pain Management Strategies</th>
</tr>
</thead>
<tbody>
<tr>
<td>• Posture</td>
</tr>
<tr>
<td>• Weight management</td>
</tr>
<tr>
<td>• Anti-inflammatory diet</td>
</tr>
<tr>
<td>• Physiologic relaxation strategies</td>
</tr>
<tr>
<td>• Self-trigger-point massage</td>
</tr>
<tr>
<td>• Education</td>
</tr>
<tr>
<td>• Fear of pain</td>
</tr>
<tr>
<td>• Catastrophizing</td>
</tr>
<tr>
<td>• Action oriented support groups</td>
</tr>
</tbody>
</table>
For patients who need more help managing their pain, non-pharmacologic therapies are the best place to start. Core therapies are active treatments such as movement therapies and psychological therapies. Complementary and Integrative Health (CIH) therapies such as acupuncture and chiropractic care, can be used widely as short term, bridging therapies with the purpose of transitioning from higher risk passive therapies (such as long-term opioid therapy) to lower risk active therapies (psychological therapies and movement therapies). Use non-pharmacologic treatments based on the type of pain the Veteran is experiencing and the type of treatment the Veteran is willing and able to perform.

**Figure 7. Non-pharmacologic Therapies**

**Psychosocial Interventions**
- Cognitive-Behavioral Therapy (CBT)
- Acceptance and Commitment Therapy (ACT)
- Progressive relaxation therapy
- Mindfulness-based Therapies
- Pain School
- Behavior groups

**Complementary and Integrative Health (CIH) Therapies**
- Acupuncture
- Massage
- Chiropractic therapy
- Ice and heat therapy
- Meditation

**Rehabilitation Therapies**
- Physical therapy
- Occupational therapy

**Exercise**
- Stretching
- Tai chi
- Swimming
- Hiking
- Walking
- Yoga
- Chair exercises
Figure 8. Similar Reduction in Pain Intensity Between Non-Pharmacologic Therapy and Non-Opioid, Low Potency Opioid and High Potency Opioid Therapy

Meta-analysis comparing different treatments for chronic pain from arthritis, low back pain, neuropathic pain and fibromyalgia. Weighted mean differences between pain intensities, using a 100 point visual analog scale (VAS), were used. Non-opioid treatments included NSAIDs, acetaminophen or paracetamol, and COX-2 inhibitors. Low potency opioids included codeine and tramadol. High potency opioids included fentanyl, morphine, oxycodone and oxymorphone. Physiotherapy included ultrasound, thermotherapy, and nerve stimulation. Psychotherapy included cognitive behavioral therapies. Medications were compared to placebo and physiotherapy and psychotherapy were compared to wait-list controls.

Figure 9. Effect of Spinal Manipulation for Acute and Chronic Low Back Pain Shows Statistically Significant Improvement in Pain Intensity and Disability After 2 Weeks

Nonrandomized prospective clinical trial evaluating the effect of spinal manipulative therapy using a single high velocity low amplitude thrust (HVLT) to the involved segment of the lumbosacral region as compared to a group receiving no treatments. Six treatments were used on alternate days over a 2 week span. No other treatments were allowed in the study. Pain VAS and disability ODI were used to determine effect.

Recommend non-pharmacologic treatments first line to Veterans with chronic pain.
Pharmacological Treatment Strategies

Non-opioid Pharmacotherapy\(^8,^9\)

Recommend addition of non-opioid pharmacotherapy in patients who continue to have intolerable pain despite using non-pharmacologic approaches. Select non-opioid therapy based on the type of pain and patient specific comorbidities.

Types of non-opioid pharmacotherapy:

- Topical Therapy
- Oral Therapy

Topical Therapy

Lowest risks for adverse effects and can provide benefit in reducing pain and improving function.

Figure 10. Topical Diclofenac is as Effective as Oral Diclofenac for Joint Pain with Fewer Side Effects\(^30\)

Randomized, double-blind, double-dummy equivalence trial of topical diclofenac solution compared to oral diclofenac (50 mg three times daily) for 12 weeks in patients with knee osteoarthritis. Pain and physical function were measured by the Western Ontario and McMaster Universities (WOMAC) VA 3.1 OA Index and pain global assessment (PGA).
**Figure 11. Topical Therapy**

<table>
<thead>
<tr>
<th><strong>TOPICALS</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>NSAIDs</strong></td>
</tr>
<tr>
<td>- Capsaicin formulations: cream or ointment</td>
</tr>
<tr>
<td>- Used for peripheral neuropathic pain and musculoskeletal pain</td>
</tr>
<tr>
<td>- Depletes substance P with daily use leading to desensitization of sensory nerve fibers and resulting in less pain</td>
</tr>
<tr>
<td>- Must use multiple times a day every day to maintain effective pain control</td>
</tr>
<tr>
<td><strong>Capsaicin</strong></td>
</tr>
<tr>
<td>- Methyl salicylate formulations: cream, ointment or patch</td>
</tr>
<tr>
<td>- Can be combined with menthol and/or camphor</td>
</tr>
<tr>
<td>- Used for local/regional effect for musculoskeletal pain</td>
</tr>
<tr>
<td>- Counterirritant causing mild inflammation which results in deeper pain relief</td>
</tr>
<tr>
<td>- Apply to intact skin</td>
</tr>
<tr>
<td><strong>Lidocaine</strong></td>
</tr>
<tr>
<td>- Lidocaine patch</td>
</tr>
<tr>
<td>- Used for peripheral neuropathic pain</td>
</tr>
<tr>
<td>- Blocks abnormal peripheral neuronal conduction</td>
</tr>
<tr>
<td>- Provides local analgesia to painful skin where the medication is applied</td>
</tr>
<tr>
<td>- Systemic absorption is very low when applied to intact skin</td>
</tr>
<tr>
<td><strong>Diclofenac formulations:</strong> gel, solution, or patch</td>
</tr>
<tr>
<td>- Used for localized pain in a joint area like the knee, ankle, shoulder, and wrist</td>
</tr>
<tr>
<td>- Produces localized anti-inflammatory effects</td>
</tr>
<tr>
<td>- Evidence does not support use for low back pain</td>
</tr>
<tr>
<td>- Less systemic side effects compared to oral NSAIDs due to minimal systemic absorption</td>
</tr>
<tr>
<td>- Safer to use in patients taking oral anticoagulants</td>
</tr>
</tbody>
</table>

Products are listed based on evidenced based recommendations. Not all products listed may be available on VA National Formulary and may require non-formulary request or prior authorization request. To view VA National Formulary: [https://www.pbm.va.gov/PBM/NationalFormulary.asp](https://www.pbm.va.gov/PBM/NationalFormulary.asp). NSAID = nonsteroidal anti-inflammatory drug.
Oral Therapy

Selection of non-opioid medications should be made based on individual patient characteristics (e.g., type of pain, other medications, comorbidities).

Figure 12. Oral Therapy

- **Acetaminophen**
  - First line therapy for the treatment of osteoarthritis and musculoskeletal pain
  - Not associated with GI ulcer, platelet or anti-inflammatory effect at doses <2000 mg/day
  - Maximum dosage 2000 mg in patients with liver disease and 4000 mg daily in patients without liver diseases
    - Caution patients about acetaminophen in over-the-counter and combination products
  - Not recommended for chronic low back pain due to lack of pain reduction

- **NSAIDs**
  - First line agents for musculoskeletal pain and acute and chronic low back pain
    - May be more effective than acetaminophen, but are associated with more side effects (e.g., GI ulceration, CV effects including MI and stroke, and renal toxicity)
  - Trial more than one NSAID, since there can be variability in patient response
  - NSAIDs are contraindicated in the setting of CABG*
  - Adding an NSAID to a pain regimen containing an opioid may have an opioid-sparing effect of approximately 20–35%

- **Antidepressants**
  - Tricyclic antidepressants (TCAs) and serotonin norepinephrine reuptake inhibitors (SNRIs)
  - First line agents for neuropathic pain such as from diabetes and for chronic musculoskeletal pain
  - Helpful in patients with concurrent chronic pain and depression

- **Anticonvulsants**
  - Gabapentin, pregabalin, carbamazepine, oxcarbazepine
  - Gabapentin and pregabalin are first line agents for diabetic nerve pain
  - Insufficient evidence to recommend for or against use for treating low back pain, including patients with radiculopathy

*Do not use perioperatively and avoid in the first 10–14 days after CABG surgery. Skeletal muscle relaxants are not recommended to treat chronic pain. CABG = coronary artery bypass graft.
### Concerns About Adverse Effects from Oral NSAIDS

---

**Figure 13. Gastrointestinal Toxicity—What are the Risks?**[^44]–[^46]

---

**Table 2. Primary Prevention of NSAID Induced GI and CV Toxicity[^43]–[^47]**

<table>
<thead>
<tr>
<th>GI Risk Factor Assessment</th>
<th>Patients with GI Risk Factors Only</th>
<th>Patient with GI Risk Factors and High Cardiovascular Risk Requiring Low Dose Aspirin</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>High Risk</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>• History of previously complicated ulcer, especially recent</td>
<td>Alternative therapy or COX-2 inhibitor + PPI* or misoprostol</td>
<td>Avoid NSAIDs or COX-2 inhibitors Use alternative therapy (e.g., acetaminophen)</td>
</tr>
<tr>
<td>• More than 2 risk factors:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>• Age &gt;65 years</td>
<td>NSAID + PPI* or misoprostol</td>
<td>NSAID/COX-2 inhibitor** + PPI* or misoprostol</td>
</tr>
<tr>
<td>• High dose NSAID therapy</td>
<td></td>
<td></td>
</tr>
<tr>
<td>• Previous history of uncomplicated ulcer</td>
<td></td>
<td></td>
</tr>
<tr>
<td>• Concurrent use of aspirin (including low dose), corticosteroids or anticoagulants</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Moderate Risk</strong></td>
<td>NSAID alone</td>
<td>NSAID/COX-2 inhibitor** + PPI* or misoprostol</td>
</tr>
<tr>
<td>• 1–2 risk factors</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Low Risk</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>• No risk factors</td>
<td>NSAID alone</td>
<td>NSAID/COX-2 inhibitor** + PPI* or misoprostol</td>
</tr>
</tbody>
</table>

*High dose and long-term use (>1 year) of PPIs has been linked to side effects including: osteoporosis, *Clostridium difficile* associated diarrhea, pneumonia, and decreased absorption of magnesium and Vitamin B12.

**Consider NSAID or COX-2 inhibitor that may have lower CV risks like naproxen, ibuprofen, or moderate dose celecoxib. CV = cardiovascular; PPI = proton pump inhibitor; COX-2 inhibitor = cyclooxygenase 2 inhibitor.

[^43]: 43
[^44]: 44
[^45]: 45
[^46]: 46
[^47]: 47
Case-control study from the Netherlands during the period of January 1998 to December 2012 in subjects who had ever used conventional NSAIDs and/or selective COX-2 inhibitors who were >18 years at first hospital admission with a primary discharge diagnosis of GI toxicity defined as peptic ulcer disease (PUD) in the GI tract. They identified 2,634 PUD cases and 5,074 age-matched controls that were current users of conventional NSAIDs or selective COX-2 inhibitors at the index date.

**Cardiovascular Risks**

- NSAIDs and COX-2 inhibitors can increase cardiovascular risk
  - Hypertension, stroke, myocardial infarction, and heart failure
  - Avoid use in patients with a history of heart failure or recent myocardial infarction
- Diclofenac and indomethacin appear to have higher risks
- Naproxen, ibuprofen, and moderate dose celecoxib (100 mg twice daily) may have a lower risk

**Renal Risks**

- Both COX-2 selective and nonselective NSAIDs are associated with renal side effects and may result in acute and chronic renal failure
- Risk factors include:
  - Elderly
  - Dehydrated state
  - Other comorbidities like congestive heart failure, diabetes, and cirrhosis
Figure 15. Options for Treating Neuropathic Pain Based on Level of Evidence\textsuperscript{39–43}

**Tricyclic Antidepressants**
- Amitriptyline, imipramine, despiramine, nortriptyline
  - NNT 3–4
  - Efficacy shown for all types of nerve pain
  - Caution in patients over 65 years of age
  - Most studies have used amitriptyline
  - Nortriptyline and despiramine have less anticholinergic effects
  - Recommended for chronic low back pain

**SNRIs**
- Duloxetine, venlafaxine
  - NNT 6–7
  - More data available for duloxetine
  - Consider in patients with comorbid depression
  - Most data for diabetic neuropathy, chemotherapy-related peripheral neuropathy and pain in multiple sclerosis
  - Duloxetine is recommended for chronic musculoskeletal pain and chronic low back pain

**Anticonvulsants**
- Gabapentin, pregabalin, carbamazepine*, oxcarbazepine*
  - NNT 7–8
  - Most data for postherpetic neuralgia, diabetic neuropathy and spinal cord injury
  - Gabapentin and pregabalin found to lack benefit for acute and chronic sciatica pain
  - Combining gabapentin with nortriptyline is more effective than either drug alone for diabetic peripheral neuropathy or postherpetic neuralgia

\*Carbamazepine and oxcarbazepine have strong evidence for treatment of trigeminal neuralgia, but evidence is weaker for other types of nerve pain. Oxcarbazepine may have fewer side effects than carbamazepine.

NNT = number needed to treat. PTSD = post-traumatic stress disorder. SNRI = serotonin norepinephrine reuptake inhibitors.
Considerations when using neuropathic pain treatments: 42-43

- Trial of the medication should last at least 12 weeks to determine effectiveness
- If the patient does not respond or has intolerable side effects
  - Taper off the medication over a few weeks
- If the patient has a partial response
  - Consider adding a second neuropathic pain agent with a different mechanism of action
  - Most evidence supports the combination of gabapentin with nortriptyline or other TCA, particularly for diabetic neuropathies

If non-pharmacologic treatments alone do not reduce a patient’s pain, consider adding non-opioid pharmacotherapy.

Step 4

Intensive Interdisciplinary Pain Rehabilitation

Intensive Interdisciplinary Pain Rehabilitation (IIPR) is a resource intensive treatment that requires active patient participation and motivation and may result in modest long-term improvements in pain and function. 52 Core elements of IIPR include integrated psychological and movement therapies with medication management. Programs may also include a variety of CIH therapies. The focus of treatment is improving physical, social, and psychological functioning and empowering the patient to implement daily use of self-management strategies.

For patients with chronic non-cancer pain who are opioid naïve, long-term opioid therapy should not be started.
It may be reasonable to use intermittent, non-daily, opioid therapy for patients with certain chronic pain conditions associated with recurrent inflammatory, ischemic, or mixed pain such as rheumatoid arthritis or sickle cell anemia. Opioid therapy should not be used in isolation and requires careful monitoring and re-evaluation at least every 3 months.

Before writing an opioid prescription:8

- Discuss the patient information guide “Taking Opioids Responsibly”
- Set expectations for pain management, develop functional goals, and discuss opioid dosing limits of ≤20 mg MEDD
- Complete the consent for Long-Term Opioid Therapy: VA Form 10-0431 Consent for Long-Term Opioid Therapy for Pain
- Perform risk mitigation strategies
  - Urine Drug Testing (UDT)
  - Prescription Drug Monitoring Program (PDMP)
- Provide opioid overdose education and offer naloxone distribution (OEND)

Setting Expectations for Pain Management

It is important to inform the Veteran that the goal is to assist them in returning to a productive and fulfilling life. Complete pain relief is not a realistic goal.

Table 3. Set Realistic Patient Expectations8

<table>
<thead>
<tr>
<th>Goal</th>
<th>Pain Reduction</th>
<th>Improved Function</th>
<th>Minimize Side Effects</th>
</tr>
</thead>
<tbody>
<tr>
<td>Education</td>
<td>• Total pain relief is not realistic</td>
<td>• Ultimate goal is to improve quality of life (QOL)</td>
<td>Educate on potential side effects and risks associated with the chosen treatment(s)</td>
</tr>
<tr>
<td></td>
<td>• Goal is to take the edge off and reduce pain by 20–30%</td>
<td>• Degree of pain that interferes with QOL is highly personal</td>
<td></td>
</tr>
</tbody>
</table>
For patients currently taking long-term opioids for chronic pain:

Close follow up is required (≤3 months) to assess the benefits vs risks, perform risk mitigation strategies, and provide OEND. Patients should be evaluated for tapering and, when risks exceed benefits, opioids should be reduced to a lower dose or discontinued. Continue optimizing whole person pain care and maintain vigilance for symptoms of opioid use and/or psychiatric comorbidities.

Table 4. Follow up for Patients on Long-Term Opioids

<table>
<thead>
<tr>
<th>Assess</th>
</tr>
</thead>
<tbody>
<tr>
<td>▪ Function, risks and benefits of opioid therapy</td>
</tr>
<tr>
<td>▪ Adverse effects</td>
</tr>
<tr>
<td>▪ Pain and functional treatment goals</td>
</tr>
<tr>
<td>▪ Adherence to treatment plan</td>
</tr>
<tr>
<td>▪ Complications or co-occurring conditions (medical, mental health, and/or SUD)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Complete risk mitigation strategies</th>
</tr>
</thead>
<tbody>
<tr>
<td>▪ Urine drug testing (UDT)</td>
</tr>
<tr>
<td>▪ Prescription drug monitoring program (PDMP)</td>
</tr>
<tr>
<td>▪ Monitoring for overdose and suicidality</td>
</tr>
<tr>
<td>▪ Opioid overdose education and naloxone distribution (OEND)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Discuss expectations and optimize comprehensive pain care plan</th>
</tr>
</thead>
<tbody>
<tr>
<td>▪ Pain reduction</td>
</tr>
<tr>
<td>▪ Improved function</td>
</tr>
<tr>
<td>▪ Minimizing side effects</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Evaluate for opioid taper</th>
</tr>
</thead>
</table>

Follow up should be performed at least every 3 months if opioid dose is stable and more frequently if needed based on risk factors.
Situations Where the Risks of Prescribing Opioids May Be the Highest

- Using opioids with medications for other conditions that increase the risk of overdose (e.g., benzodiazepines)
- Concerns about opioid use disorder (OUD), substance use disorder (SUD), or diversion of opioids
- Patient nonadherence with opioid safety measures and risk mitigation strategies
- Patient is not participating in comprehensive care plan
- Use of opioids in Veterans younger than 30 years of age
- Opioid dose is over the maximal recommended dose (≥90 mg MEDD)
- Pain condition not effectively improved with opioids or opioids are not providing a clinically meaningful improvement in function
- Pain conditions which may be worsened by opioids (e.g., fibromyalgia, headache)
- Unmanageable side effects

Comorbidities

It is important to address other comorbidities that can complicate pain management. Functioning will not improve without addressing other comorbidities that can worsen pain and/or pain perception or increase the risks of opioid therapy.

Figure 16. Addressing Comorbidities
Evaluate Patients for Suicidality

Patients with chronic pain have an increased risk of suicide

✓ **Assess** patient for risk factors including mental health diagnoses, past suicide attempts, intentional self-harm, traumatic brain injury, and psychosocial factors (e.g., recent job loss, legal charges)

✓ **Ask** about suicidal ideation, intent, plan, and past attempts

✓ **Refer** as needed for treatment of depression or other mental health disorders, and provide patients with supportive psychological therapy using safe drug treatments

Opioid Overdose Education and Naloxone Distribution (OEND)

- Education and training for patients on how to prevent, recognize, and respond to an opioid overdose
- Provide overdose education and naloxone prescriptions to all patients taking opioids chronically for pain
  - Factors placing patients at a higher risk for overdose
    - Concurrent opioid and benzodiazepine use
    - Doses of opioids over 50 mg MEDD
    - Patients with OUD
    - Patients tapering dose of opioids due to lower tolerance
- Naloxone is available for outpatient dispensing

Figure 17. OEND and Basic Steps for Responding to an Opioid Overdose

1. Check for a response.
2. Give naloxone and Call 911.
3. Ensure airway is open.
4. Consider naloxone again.*
5. Place in recovery position.

* If the person doesn’t start breathing in 2–3 minutes, give the second dose of naloxone; naloxone wears off quickly so a second dose may also be needed if the person stops breathing again.
A change in treatment plan must be considered for all Veterans who have an opioid overdose.\textsuperscript{54}

Risk mitigation strategies, including UDT, checking state PDMP, providing OEND, should be done at least annually in all Veterans prescribed opioids for pain.

**Does the Dose of Opioid Matter?**

*Figure 18. Exponential Increase in the Incident Rate of Opioid Overdose Death Based on MEDD\textsuperscript{55}*

Risks for overdose and death begin to increase at a range of 20–50 mg MEDD\textsuperscript{8,39,55}

---

Observational cohort study of 2,182,374 patients in North Carolina prescribed opioids for pain. Opioid analgesics were dispensed to 22.8\% of residents. Of the 2,182,374 patients prescribed opioids there were 478 overdose deaths. Mortality rates increased over the range of MEDD. In addition, 80\% of opioid analgesic patients also received benzodiazepines. Rates of overdose death among patients with concurrent opioid and benzodiazepine use were 10 times higher than those using opioids alone.

When opioids are prescribed chronically, it is preferable to keep doses below 20–50 mg MEDD. Reassess risks and benefits for all patients on long-term opioid therapy and if functional benefits do not clearly outweigh risks, consider a slow taper to a reduced dose or to discontinuation.
Opioid and Benzodiazepine Combinations – These can be lethal!

Opioids when co-administered with substances with sedative properties, like benzodiazepines, can result in unintentional fatal outcomes.\(^{56,57}\)

Figure 19. Opioid Overdose with Co-Administered Benzodiazepine: The Risk Increases with Increasing Doses of the Benzodiazepine\(^{56}\)

This case-cohort study (2004–2009) found that of the 2,400 Veterans in the study population who died from an opioid overdose death, 1,185 (49%) died during a period in which they had been prescribed concurrent benzodiazepines. Risk of overdose increased as daily benzodiazepine dose increased.

Figure 20. Opioid Overdoses Increase When Patients Use Opioids in Combination with Benzodiazepines\(^{57}\)

Adjusted incidence of opioid overdose for patients taking opioids with and without benzodiazepines. Adjusted incidence incorporates controls for year, sex, age and characteristics. Incidence of overdose increases when opioids are used in combination with benzodiazepines, particularly with chronic opioid use.

Avoid prescribing opioids and benzodiazepines in combination.
Opioid Taper

Consider tapering opioids in Veterans where the risk of continuing the opioid outweighs the benefit of continuing the opioid. When a taper is necessary, the first step is talking with the Veteran about the taper.

- Explain the risks of opioid therapy as they apply to the Veteran and why tapering is necessary.
- Review how the taper will be done and provide support during the taper.
- Pauses in the taper may be necessary for the Veteran to adjust to the new dose before further reductions are made.
- If the Veteran has opioid use disorder (OUD) or shows behaviors consistent with OUD, do not start an opioid taper. First, the provider should:
  - Address OUD and consider prescribing medication assisted treatment (MAT) or
  - Connect the Veteran with a substance use disorder clinic who can provide OUD services

Table 5. Starting the Conversation with Veterans About Tapering Opioids

<table>
<thead>
<tr>
<th>Conversation</th>
<th>Instead of this:</th>
<th>Consider saying this:</th>
</tr>
</thead>
<tbody>
<tr>
<td>Starting the conversation</td>
<td>The VA wants me to stop your oxycodone. My hands are tied.</td>
<td>I am concerned about your safety with the oxycodone I am prescribing you for pain.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>May I talk to you more about this?</td>
</tr>
<tr>
<td>Continuing the conversation</td>
<td>I know you have pain, but I cannot give you this medicine anymore. You will have</td>
<td>Have you heard about the increase in deaths from overdose in people taking opioids like</td>
</tr>
<tr>
<td></td>
<td>to figure something else out.</td>
<td>oxycodone?</td>
</tr>
<tr>
<td></td>
<td></td>
<td>How do you feel about this?</td>
</tr>
<tr>
<td>Introduce other options for</td>
<td>You know, acetaminophen would work just as well. How about you go to the drug</td>
<td>There are other treatments and medications we can try for your pain.</td>
</tr>
<tr>
<td>pain</td>
<td>store and pick up some of that?</td>
<td>They are safer and could be as effective and might be even more effective than the</td>
</tr>
<tr>
<td></td>
<td></td>
<td>oxycodone.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>May I tell you more about this?</td>
</tr>
<tr>
<td>Conversation</td>
<td>Instead of this:</td>
<td>Consider saying this:</td>
</tr>
<tr>
<td>------------------------------------------------</td>
<td>--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------</td>
<td>---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td><strong>Talk about tapering the opioid</strong></td>
<td>I am going to give you a prescription for X tablets of oxycodone. For the first week, cut your dose in half. Then the next week, reduce by another half and keep doing that until you are off. We should have it all done by the end of the month.</td>
<td>As we start the new treatment, I recommend that we start with a very small reduction in oxycodone which will help move your dose to a safer level. This would involve reducing by X tablets a week/month (5–10% reduction per month). Our experience and studies show that as we reduce the oxycodone gradually and add other more effective treatments, your pain levels will likely stay the same. In some cases, patients have experienced some discomfort in the first few weeks of the taper but it usually improves with time. What are your thoughts on reducing the oxycodone?</td>
</tr>
</tbody>
</table>

| Provide support and follow up                  | I will schedule you to follow up in 6 months.                                                                                                                                                                                                                                                                                                      | In 2 weeks, the PACT team (nurse, pharmacist, or provider) will give you a call and see how you are doing with the lower dose of oxycodone and the new treatment.                                                                                                                                                                                                                         |

| **Talk about possible emergence of OUD during an opioid taper** |                                                                                                                                                                                                                                                                                                                                          | Your brain has been exposed to and has adapted to these medications over the past several years. As the opioid dose is lowered,  
  - your brain may react by producing a strong desire to take more opioids or  
  - you may find that you cannot take your mind off opioids or are having a difficult time taking the opioids as prescribed  
If you notice any of these things, please contact us right away so we can help you.  
It is important you know that we have effective treatments in case you notice any of these symptoms.                                                                                       |

For more information: See VA PBM Academic Detailing Opioid Taper Tool  
(http://www.pbm.va.gov/PBM/academicdetailingservice/Pain_and_Opioid_Safety.asp).
Some Patients Will Struggle with Tapering

What might this mean?

- The speed of the taper may be too fast
  - Reducing opioid doses 5–20% per month is appropriate for most patients but some may need a slower taper of 2–5% reduction per month
  - Pausing for 2–4 weeks after a dose reduction may be necessary in some patients to allow them to adjust to the new dose
- The Veteran may be anxious and fearful about the taper and may need more counseling and support during the taper
- Co-occurring mental health conditions may be worsening during the taper and should be addressed
- The Veteran may have opioid use disorder (OUD)
  - Screen for OUD
  - If patient has OUD, provide or refer for medication assisted treatment (MAT)
- The Veteran may need other non-pharmacologic and non-opioid treatments
- The Veteran may be diverting medications

If the Veteran has OUD, pain treatments will need to be tailored to ensure safety and reduce overdose risks. Consultation with a pain specialist and a behavior health provider is recommended to determine the most appropriate treatment plan that includes relapse-prevention strategies.\(^{3,58–60}\)

Assess for OUD and if present, offer or refer for medication assisted treatment and counseling prior to starting or continuing an opioid taper.
### Summary

<table>
<thead>
<tr>
<th>Icon</th>
<th>Text</th>
</tr>
</thead>
<tbody>
<tr>
<td><img src="image" alt="No Opioids" /></td>
<td>Opioids are no longer recommended for treatment of chronic pain.</td>
</tr>
<tr>
<td><img src="image" alt="Non-pharmacologic" /></td>
<td>Non-pharmacologic and non-opioid treatments should be used first line for most types of pain.</td>
</tr>
<tr>
<td><img src="image" alt="Risk Evaluation" /></td>
<td>In patients already prescribed opioids for chronic pain, weigh the risks and benefits of continued use.</td>
</tr>
<tr>
<td><img src="image" alt="Follow-up" /></td>
<td>Follow up with all patients taking chronic opioids at least every 3 months and use risk mitigation strategies including UDT, PDMP review, and OEND.</td>
</tr>
<tr>
<td><img src="image" alt="Tapering" /></td>
<td>If the risks of continuing the opioid are high, discuss slowly tapering the opioid (5–20% per month) and using non-pharmacologic and non-opioid alternatives.</td>
</tr>
<tr>
<td><img src="image" alt="Screen for OUD" /></td>
<td>Screen for OUD in patients struggling with tapering opioids and showing high risk behaviors. Medication assisted treatment with buprenorphine/naloxone or methadone might be necessary.</td>
</tr>
</tbody>
</table>
References


11. Ong AD, Zautra AJ, Reid MC. Chronic pain and the adaptive significance of positive emotions. Am Psychol. 2015;70:283–284


U.S. Department of Veterans Affairs

This reference guide was created to be used as a tool for VA providers and is available to use from the Academic Detailing Service SharePoint.

These are general recommendations only; specific clinical decisions should be made by the treating provider based on an individual patient’s clinical condition.

VA PBM Academic Detailing Service Email Group
PharmacyAcademicDetailingProgram@va.gov

VA PBM Academic Detailing Service SharePoint Site
https://vaww.portal2.va.gov/sites/ad/SitePages/Home.aspx

VA PBM Academic Detailing Public Website
http://www.pbm.va.gov/PBM/academicdetailingservicehome.asp